09:05 AM EST - Oncolytics Biotech Inc : Today announces recent operational highlights and financial results for the second quarter ended June 30, 2022. Highlights include; achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients; clinical biomarker data show pelareorep remodeling tumor microenvironments to improve prognosis and decrease the risk of recurrence in HR+/HER2- breast cancer patients. Cash and cash equivalents of 33.7 million (CAD) provides the projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer. Oncolytics Biotech Inc
shares T.ONC are trading down one cent at $1.66.
